The last two listings of the year are expected to create a lot of buzz on the Street, as both issues saw strong participation of investors.

Merchant bankers believe that the issue will get fully subscribed on Monday with more retail and FII bids coming in at the last minute.

Healthcare services major Narayana Hrudayalaya's initial public offer was subscribed only 30 per cent on the second day of the offer today.

Dr Lal's IPO too was a huge success with 33.41 times oversubscription. The price band was fixed at Rs 540-550 per share for the Rs 638 cror...

The success of issues like Alkem Labs and PathLabs means that cos have raised Rs 13K crore so far from the IPO market in 2015.

IPO of drug maker Alkem Laboratories and diagnostic chain Dr Lal PathLabs elicited robust investor response, with 44.23 times and 33.31 tim...

The Rs 1,350-crore IPO received bids for 1,27,74,230 shares against the total issue size of 90,87,084 shares, according to data available w...

Both Alkem and Dr Lal PathLabs are very good companies, but perhaps valuations are looking a little expensive, says Shenoy.

The initial public offering of Alkem Laboratories was subscribed 35 per cent on the first day of the issue today.

"We have had good demand from anchor investors — both from domestic mutual funds and FIIs. We are very happy to see this kind of response."

With many unlisted cos in sector, chances of them tapping mkt looks high: Nomura Fin's Oza.

The successful listing of of InterGlobe Aviation and SH Kelkar has seen a rise in premiums for upcoming IPOs in the grey mkt.

Drug maker Alkem Laboratories has received capital markets regulator Sebi's approval to raise an estimated Rs 1,500-3,500-crore through an ...

Without getting into specifics, the Securities and Exchange Board of India (Sebi) has said it's awaiting response from lead managers for th...

Alkem Laboratories filed draft papers with capital markets regulator Sebi to raise an estimated Rs 1,500-3,500 crore through an IPO.

"Alkem will soon file its draft paper with capital market regulator Securities and Exchange Board of India (Sebi) to float an IPO," sources...

80% of the company's revenues currently come from domestic operations and now it's main focus is on the US market.